100,000 people are expected to benefit each year! Optical Valley enterprise independent research and development "heart occluder delivery system" approved for listing



On June 12, Optical Valley enterprise WuhanVickor Medical Technology Co., LTD. (hereinafter referred to as "Vickor Medical"), the self-developed "heart closure device delivery system" was officially approved by the State Medical Products Administration, and the successful approval is an important step for VECO Medical to formally explore the road to commercialization.

The biggest design highlight of this occluder delivery system is the optimization of the delivery sheath head.

Compared with traditional products, the length of its head end is shortened, making the overall curvature more accurately match the anatomic shape of the atrial septum. When the surgeon performs the closure of atrial septal defect and patent foramen ovale, the sheath tube is easier to pass through the diseased site. Especially for the ultrasonically guided operation, the success rate of the septum is greatly improved, and the operation time is significantly saved, which has significant clinical application value.

Due to the compact curvature of the head end, the operation space of the sheath in the heart cavity is increased, and the complications such as pericardial tamponade are avoided to the maximum extent, and the surgical safety is improved.

Vickor Medical is an innovative company focusing on cardiovascular and cerebrovascular diseases, especially in the field of heart failure and structural heart disease intervention. In line with the concept of combining medical industry and independent innovation, the company is committed to building a comprehensive integrated platform for the treatment of cardiovascular and cerebrovascular diseases.

In 2018, Vickor Medical was registered and established in Wuhan Optics Valley, a city with a strong biomedical industry atmosphere, focusing on the innovative development of cardiac implant devices in the field of cardiovascular and cerebrovascular diseases, especially structural heart disease.

Shang Xiaoke, founder of VECO Medical, said: "The clinical demand for heart occltors is high, with about 100,000 new patients in China every year. And the technology of the stopper is relatively mature, and the products at home and abroad are available on the market, and the degree of application and acceptance is also high."